As HSE, Government, and Respreeza drugmaker bicker, one man’s life hangs in the balance

John Hannan has been a ‘guinea pig’ for Respreeza for 11 years. Now, due to the reported €84k-a-year cost, he faces losing access to a drug that’s proven a lifesaver. He talks to Health Correspondent Catherine Shanahan

As HSE, Government, and Respreeza drugmaker bicker, one man’s life hangs in the balance

John Hannan sits in a chair as a drug, diluted in a bag of fluid, drips slowly into his veins. There are three witnesses to this event: Myself, a photographer and the nurse who set up his infusion.

It’s not too far a stretch to say the image is slightly suggestive of a prison execution, because, in a way, John feels a bit like an inmate on Death Row. He sits in a chair at Mallow Primary Healthcare Centre as four-and-a-bit vials of human alpha1-proteinase inhibitor, brand name Respreeza, works its way into his bloodstream for what looks like the final time.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited